IRIS Accounts Production v24.3.2.46 09602276 director 1.2.23 31.1.24 31.1.24 false true false false true false Fair value model Ordinary 1.00000 Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh096022762023-01-31096022762024-01-31096022762023-02-012024-01-31096022762022-01-31096022762022-02-012023-01-31096022762023-01-3109602276ns15:EnglandWales2023-02-012024-01-3109602276ns14:PoundSterling2023-02-012024-01-3109602276ns10:Director12023-02-012024-01-3109602276ns10:PrivateLimitedCompanyLtd2023-02-012024-01-3109602276ns10:SmallEntities2023-02-012024-01-3109602276ns10:AuditExempt-NoAccountantsReport2023-02-012024-01-3109602276ns10:SmallCompaniesRegimeForDirectorsReport2023-02-012024-01-3109602276ns10:SmallCompaniesRegimeForAccounts2023-02-012024-01-3109602276ns10:FullAccounts2023-02-012024-01-3109602276ns10:OrdinaryShareClass12023-02-012024-01-3109602276ns10:CompanySecretary12023-02-012024-01-3109602276ns10:RegisteredOffice2023-02-012024-01-3109602276ns5:CurrentFinancialInstruments2024-01-3109602276ns5:CurrentFinancialInstruments2023-01-3109602276ns5:ShareCapital2024-01-3109602276ns5:ShareCapital2023-01-3109602276ns5:RetainedEarningsAccumulatedLosses2024-01-3109602276ns5:RetainedEarningsAccumulatedLosses2023-01-3109602276ns5:FurnitureFittings2023-01-3109602276ns5:FurnitureFittings2023-02-012024-01-3109602276ns5:FurnitureFittings2024-01-3109602276ns5:FurnitureFittings2023-01-3109602276ns5:CostValuation2023-01-3109602276ns5:WithinOneYearns5:CurrentFinancialInstruments2024-01-3109602276ns5:WithinOneYearns5:CurrentFinancialInstruments2023-01-3109602276ns10:OrdinaryShareClass12024-01-31096022761ns10:Director12023-01-31096022761ns10:Director12022-01-31096022761ns10:Director12023-02-012024-01-31096022761ns10:Director12022-02-012023-01-31096022761ns10:Director12024-01-31096022761ns10:Director12023-01-31
REGISTERED NUMBER: 09602276 (England and Wales)















Unaudited Financial Statements

for the Year Ended 31 January 2024

for

HEALTHPHARM LTD

HEALTHPHARM LTD (REGISTERED NUMBER: 09602276)

Contents of the Financial Statements
for the Year Ended 31 January 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


HEALTHPHARM LTD

Company Information
for the Year Ended 31 January 2024







Director: I S Bajwa





Secretary: K K Bajwa





Registered office: Floor 3
Northern Assurance Buildings
9-21 Princess Street
Manchester
Greater Manchester
M2 4DN





Registered number: 09602276 (England and Wales)





Accountants: Evelyn Partners (Manchester) Limited
Accountants
Northern Assurance Buildings
9-21 Princess Street
Manchester
M2 4DN

HEALTHPHARM LTD (REGISTERED NUMBER: 09602276)

Balance Sheet
31 January 2024

2024 2023
Notes £    £    £    £   
Fixed assets
Tangible assets 5 11,807 14,337
Investments 6 287,584 287,584
Investment property 7 485,860 -
785,251 301,921

Current assets
Debtors 8 1,235,039 770,801
Cash at bank 70,604 1,081,085
1,305,643 1,851,886
Creditors
Amounts falling due within one year 9 46,925 134,847
Net current assets 1,258,718 1,717,039
Total assets less current liabilities 2,043,969 2,018,960

Capital and reserves
Called up share capital 10 1 1
Retained earnings 2,043,968 2,018,959
Shareholders' funds 2,043,969 2,018,960

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the director and authorised for issue on 8 January 2025 and were signed by:





I S Bajwa - Director


HEALTHPHARM LTD (REGISTERED NUMBER: 09602276)

Notes to the Financial Statements
for the Year Ended 31 January 2024


1. Statutory information

Healthpharm Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. Statement of compliance

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

3. Accounting policies

Basis of preparing the financial statements
The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about Healthpharm Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Fixtures and fittings -15% straight line

Tangible fixed assets are stated at cost (or deemed cost) or valuation less accumulated depreciation and accumulated impairment losses.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Debtors and creditors receivable / payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the Profit and Loss Account in administrative expenses.

HEALTHPHARM LTD (REGISTERED NUMBER: 09602276)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2024


3. Accounting policies - continued

Fixed asset investments
Interests in subsidiaries, associates and jointly controlled entities are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Transaction costs are expensed to profit or loss as incurred. Changes in fair value are recognised in other comprehensive income except to the extent that a gain reverses a loss previously recognised in profit or loss, or a loss exceeds the accumulated gains recognised in equity; such gains and loss are recognised in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a longer-term interest and where the company has a significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

4. Employees and directors

The average number of employees during the year was 1 (2023 - 1 ) .

5. Tangible fixed assets
Fixtures
and
fittings
£   
Cost
At 1 February 2023
and 31 January 2024 16,867
Depreciation
At 1 February 2023 2,530
Charge for year 2,530
At 31 January 2024 5,060
Net book value
At 31 January 2024 11,807
At 31 January 2023 14,337

6. Fixed asset investments
Other
investments
£   
Cost
At 1 February 2023
and 31 January 2024 287,584
Net book value
At 31 January 2024 287,584
At 31 January 2023 287,584

HEALTHPHARM LTD (REGISTERED NUMBER: 09602276)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2024


7. Investment property
Total
£   
Fair value
Additions 485,860
At 31 January 2024 485,860
Net book value
At 31 January 2024 485,860

8. Debtors: amounts falling due within one year
2024 2023
£    £   
Trade debtors 4,800 -
Amounts owed by group undertakings 1,097,510 750,642
Other debtors 132,729 20,159
1,235,039 770,801

9. Creditors: amounts falling due within one year
2024 2023
£    £   
Trade creditors 13,424 -
Corporation tax 29,294 13,620
Directors' current accounts - 117,053
Accruals and deferred income 4,207 4,174
46,925 134,847

10. Called up share capital

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
1 Ordinary £1 1 1

11. Director's advances, credits and guarantees

The following advances and credits to a director subsisted during the years ended 31 January 2024 and 31 January 2023:

2024 2023
£    £   
I S Bajwa
Balance outstanding at start of year (117,054 ) 38,306
Amounts advanced 246,394 26,037
Amounts repaid (42,545 ) (181,397 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 86,795 (117,054 )

There is interest payable on the amount outstanding.